Sodium-glucose cotransporter 2 inhibitors (SGLT2i), initially developed as antihyperglycemic agents, have now become foundational therapy for HF across the ejection-fraction spectrum, independent of diabetes status. Here, SLC5A2 is linked to hydrops fetalis.